JP2003534281A - Ｔ細胞媒介性及び炎症性疾患の治療における使用のためのアポトーシス体 - Google Patents

Ｔ細胞媒介性及び炎症性疾患の治療における使用のためのアポトーシス体

Info

Publication number
JP2003534281A
JP2003534281A JP2001585780A JP2001585780A JP2003534281A JP 2003534281 A JP2003534281 A JP 2003534281A JP 2001585780 A JP2001585780 A JP 2001585780A JP 2001585780 A JP2001585780 A JP 2001585780A JP 2003534281 A JP2003534281 A JP 2003534281A
Authority
JP
Japan
Prior art keywords
cells
apoptotic
patient
bodies
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001585780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534281A5 (enExample
Inventor
ダニエル・ソーダー
アルカディー・マンデル
アンソニー・イー・ボルトン
Original Assignee
ヴァソゲン アイルランド リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァソゲン アイルランド リミテッド filed Critical ヴァソゲン アイルランド リミテッド
Publication of JP2003534281A publication Critical patent/JP2003534281A/ja
Publication of JP2003534281A5 publication Critical patent/JP2003534281A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
JP2001585780A 2000-05-25 2001-05-25 Ｔ細胞媒介性及び炎症性疾患の治療における使用のためのアポトーシス体 Withdrawn JP2003534281A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2,309,518 2000-05-25
CA 2309518 CA2309518A1 (en) 2000-05-25 2000-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
PCT/CA2001/000758 WO2001089536A2 (en) 2000-05-25 2001-05-25 Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2003534281A true JP2003534281A (ja) 2003-11-18
JP2003534281A5 JP2003534281A5 (enExample) 2008-07-10

Family

ID=4166254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001585780A Withdrawn JP2003534281A (ja) 2000-05-25 2001-05-25 Ｔ細胞媒介性及び炎症性疾患の治療における使用のためのアポトーシス体

Country Status (11)

Country Link
US (1) US20020051771A1 (enExample)
EP (2) EP1289534B1 (enExample)
JP (1) JP2003534281A (enExample)
AT (1) ATE311191T1 (enExample)
AU (1) AU2001261986A1 (enExample)
CA (1) CA2309518A1 (enExample)
DE (1) DE60115432T2 (enExample)
DK (1) DK1289534T3 (enExample)
ES (1) ES2254424T3 (enExample)
TW (1) TWI249404B (enExample)
WO (1) WO2001089536A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507208A (ja) * 2015-02-18 2018-03-15 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP2019505552A (ja) * 2016-02-18 2019-02-28 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
CA2457015C (en) * 2001-08-13 2012-03-13 Richard L. Edelson Method for inducing selectively suppressed immune response
US7727523B2 (en) * 2001-08-13 2010-06-01 Yale University Method for suppressing immune system response to transplanted tissue or cells
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
US8524495B2 (en) 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CA2893962C (en) * 2012-12-06 2021-04-06 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
WO2023209709A1 (en) * 2022-04-27 2023-11-02 Enlivex Therapeutics Rdo Ltd Apoptotic cell - chemotherapy combination therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018507208A (ja) * 2015-02-18 2018-03-15 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP2021100955A (ja) * 2015-02-18 2021-07-08 エンリヴェックス セラピューティクス リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP7157839B2 (ja) 2015-02-18 2022-10-20 エンリヴェックス セラピューティクス アールディーオー リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP2022188225A (ja) * 2015-02-18 2022-12-20 エンリヴェックス セラピューティクス アールディーオー リミテッド 癌治療のための免疫療法とサイトカイン制御療法との組み合わせ
JP2019505552A (ja) * 2016-02-18 2019-02-28 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
JP2021119197A (ja) * 2016-02-18 2021-08-12 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
JP7223055B2 (ja) 2016-02-18 2023-02-15 エンリヴェックス セラピューティクス アールディーオー リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法

Also Published As

Publication number Publication date
US20020051771A1 (en) 2002-05-02
WO2001089536A2 (en) 2001-11-29
EP1289534A2 (en) 2003-03-12
AU2001261986A1 (en) 2001-12-03
ES2254424T3 (es) 2006-06-16
ATE311191T1 (de) 2005-12-15
DK1289534T3 (da) 2006-03-20
WO2001089536A3 (en) 2002-08-01
DE60115432T2 (de) 2006-08-24
EP1289534B1 (en) 2005-11-30
HK1055079A1 (en) 2003-12-24
CA2309518A1 (en) 2001-11-25
EP1669081A1 (en) 2006-06-14
TWI249404B (en) 2006-02-21
DE60115432D1 (de) 2006-01-05

Similar Documents

Publication Publication Date Title
US20080131416A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
Jiang et al. Human umbilical cord MSC‐derived exosomes suppress the development of CCl4‐induced liver injury through antioxidant effect
EP1289534B1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
JP2008505104A (ja) 免疫抑制性エキソソーム
Li et al. Exosome‐based targeted RNA delivery for immune tolerance induction in skin transplantation
US20080063631A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
Smetana et al. Ring shaped nucleoli in liver cells of rats after treatment with actinomycin D
Yuan et al. Gastrodin Ameliorates Acute Rejection via IRE1α/TRAF2/NF‐κB in Rats Receiving Liver Allografts
Abdeltawab et al. Effect of Moringa oleifera and ivermectin nanoparticles on the immunopathological response during experimental trichinosis in mice
Han et al. Injectable Nano‐Micron AKBA Delivery Platform for Treatment of Tendinopathy in a Rat Model
CA2409960A1 (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CN117586954A (zh) 槲皮素、myh9蛋白新应用
WO1989002918A1 (en) Process for selectively modulating the expression and function of a cell-surface determinant and production of novel human cells produced thereby
HK1055079B (en) Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
HK1093428A (en) Apoptotic entities for use in treatment of t-cell-mediated und inflammatory disorders
US20070298020A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
WO2002012453A1 (de) Verfahren zur reduzierung von spezifischen immunreaktionen
CA2409992A1 (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
HK1055080B (en) Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2409994A1 (en) Apoptotic entities for use in treatment of endothelium dysfunction disorders
EP1179587A1 (de) Verfahren zur Reduzierung von spezifischen Immunreaktionen
DE102004047262A1 (de) Pharmazeutisches Mittel umfassend Blutprodukte und deren Verwendung als Injektions- oder Infusionsmittel zur Prophylaxe und Behandlung von Defekten des Immunsystems beim Menschen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051117

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20051117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20051212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080818